Physician profile
Andrea Bourke
NPI 1194070466
$5,186.68
in general payments reported to CMS, 2019-2025
28 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $483 · 2023: $1,874 · 2024: $1,223 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.05 |
| Education | $233.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $848.19 | 2021-2025 | Tremfya |
| Abbvie INC. | $654.68 | 2021-2025 | |
| Galderma Laboratories, L.P. | $443.44 | 2023-2025 | Aklief, Twyneo, Epsolay |
| Leo Pharma INC. | $353.03 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $293.12 | 2021-2024 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $275.22 | 2023-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $249.12 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $224.15 | 2023-2025 | Zoryve |
| Incyte Corporation | $213.59 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $208.94 | 2021-2024 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $179.03 | 2022-2024 | |
| Genzyme Corporation | $173.37 | 2023-2025 | |
| Ucb, INC. | $134.90 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $124.29 | 2024-2025 | Ycanth |
| Dermavant Sciences, INC. | $120.37 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $116.70 | 2023-2025 | |
| Organon LLC | $115.25 | 2025 | Vtama |
| Lilly USA, LLC | $114.11 | 2022-2024 | Taltz, Ebglyss, Olumiant |
| Organogenesis INC. | $86.26 | 2024-2025 | Novachor, Puraply Wound Matrix, Cygnus Dual |
| Mayne Pharma Commercial LLC | $43.65 | 2021-2023 | |
| Journey Medical Corporation | $38.72 | 2022-2023 | |
| Genentech USA, INC. | $33.54 | 2025 | Xolair |
| Fresenius Kabi USA, LLC | $31.40 | 2023 | |
| Botanix Sb INC | $26.22 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $24.84 | 2023 | |
| Epi Health, LLC | $24.01 | 2022 | |
| Almirall LLC | $22.96 | 2025 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Bourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.